Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryCommunity-Care botulinum toxin Coverage Update | O…
    Ask Trek AI about this page
    CurrentCommunity-CarePolicy N/A

    Botulinum toxin products — medical coverage criteria

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage, prior authorization, quantity limits, and continuation criteria for botulinum toxin products (preferred: Botox, Dysport, Xeomin) across neurologic and related indications for Community-Care members in North Carolina.

    Policy Summary
    PayerCommunity-Care
    PolicyBotulinum toxin products — medical coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewAug 1, 2025
    Next Review DateAug 1, 2025
    Key ActionObtain prior authorization and document indication-specific diagnostic and trial criteria (including pediatric weight when applicable).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    9+indications
    12 weeks

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    min dosing interval
    Appendix 1quantity limits
    J0585–J0589HCPCS codes

    Coverage and Medical Necessity Criteria

    Initial Therapy

    Covered when ALL of the following indication-specific criteria are met

    Chronic sialorrhea - Initial: Member has a diagnosis of chronic sialorrhea AND if requested drug is onabotulinumtoxinA (Botox) then trial of incobotulinumtoxinA (Xeomin) was ineffective, contraindicated, or not tolerated AND dosing limited to every 16 weeks.
    Cervical dystonia - Initial: Diagnosis of cervical dystonia AND if the requested drug is onabotulinumtoxinA (Botox), ONE of the following applies: (a) trials of incobotulinumtoxinA (Xeomin) and abobotulinumtoxinA (Dysport) were ineffective, contraindicated, or not tolerated OR (b) member is aged 16 to <18 years AND dosing limited to every 12 weeks.
    Blepharospasm - Initial: Diagnosis of blepharospasm AND if the requested drug is onabotulinumtoxinA (Botox), ONE of the following applies: (a) trial of incobotulinumtoxinA (Xeomin) was ineffective, contraindicated, or not tolerated OR (b) member is aged 12 to <18 years AND dosing limited to every 12 weeks.
    Upper limb spasticity - Initial: Diagnosis of upper limb spasticity AND if the requested drug is onabotulinumtoxinA (Botox), BOTH incobotulinumtoxinA (Xeomin) and abobotulinumtoxinA (Dysport) trials were ineffective, contraindicated, or not tolerated AND dosing limited to every 12 weeks.
    Lower limb spasticity - Initial: Diagnosis of lower limb spasticity AND if the requested drug is onabotulinumtoxinA (Botox), trial of abobotulinumtoxinA (Dysport) was ineffective, contraindicated, or not tolerated AND dosing limited to every 12 weeks.
    Strabismus - Initial: Diagnosis of strabismus AND disease interferes with normal visual development AND aged ≥ 12 years AND dosing limited to every 12 weeks.
    Overactive bladder/Urinary incontinence - Initial: Diagnosis of overactive bladder OR urinary incontinence AND aged ≥ 18 years AND trial of two medications from anticholinergic or beta-3 adrenergic agonist classes were ineffective, contraindicated, or not tolerated AND dosing limited to every 12 weeks.
    Axillary hyperhidrosis - Initial: Diagnosis of axillary hyperhidrosis AND aged ≥ 18 years AND dosing limited to every 12 weeks.
    Neurogenic detrusor overactivity - Initial: Diagnosis of neurogenic detrusor overactivity AND aged ≥ 5 years AND trial of two anticholinergic medications was ineffective, contraindicated, or not tolerated AND dosing limited to every 12 weeks.
    Chronic migraine prophylaxis - Initial: Diagnosis of chronic migraine AND aged ≥ 18 years AND prescriber meets one of the listed specialist/credential criteria AND fifteen or more headache days per month for at least the previous 3 months AND trial of topiramate was ineffective, contraindicated, or not tolerated AND one of: (a) botulinum toxin will not be used concomitantly with a CGRP inhibitor OR (b) botulinum toxin will be used concomitantly with a CGRP inhibitor and the member has failed at least three months of individual therapy with either a botulinum toxin for migraine prevention or the CGRP inhibitor requested for concomitant use AND dosing limited to every 12 weeks.

    Continuation Therapy

    Covered when ALL of the following are met for continuation of chronic migraine therapy

    Chronic migraine - Continuation: Member has a diagnosis of chronic migraine AND experienced a meaningful improvement in frequency and/or severity of migraine AND one of the following: (a) botulinum toxin will not be used concomitantly with a CGRP inhibitor for migraine prevention OR (b) botulinum toxin will be used concomitantly with a CGRP inhibitor and the member has failed at least 3 months of individual therapy with either a botulinum toxin for migraine prevention or the CGRP inhibitor requested for concomitant use.

    Products used for cosmetic purposes are excluded from plan benefits. Examples of excluded cosmetic indications include onabotulinumtoxinA (Botox Cosmetic) when used for aesthetic facial lines such as moderate to severe glabellar lines, lateral canthal lines, platysma bands, and forehead lines. PrabotulinumtoxinA (Jeuveau) for temporary improvement of moderate to severe glabellar lines is also excluded. IncobotulinumtoxinA (Xeomin) used for the appearance of upper facial lines (glabellar, horizontal forehead, or lateral canthal lines) and daxibotulinumtoxinA-lanm (Daxxify) for temporary improvement of moderate to severe glabellar lines are likewise not covered under the cosmetic use exclusion.

    Use of botulinum toxin for cosmetic or aesthetic indications described in this policy is considered not covered. Specific excluded products and labeled aesthetic uses include: onabotulinumtoxinA (Botox Cosmetic) for facial lines (glabellar, lateral canthal, platysma, forehead), prabotulinumtoxinA (Jeuveau) for glabellar lines, incobotulinumtoxinA (Xeomin) for upper facial lines, and daxibotulinumtoxinA-lanm (Daxxify) for glabellar lines.

    Billing Codes and Quantity Limits

    Applicable HCPCS CodesHCPCS
    J0585Injection, onabotulinumtoxina, 1 unit
    J0586Injection, abobotulinumtoxina, 5 units
    J0587Injection, rimabotulinumtoxinb, 100 units
    J0588Injection, incobotulinumtoxin a, 1 unit
    J0589Injection, daxibotulinumtoxinA-lanm, 1 unit
    Cervical dystonia (Botox) — dosing/interval
    Maximum unitsUp to 300 units
    Dosing intervalEvery 12 weeks
    Product specifiedonabotulinumtoxinA (Botox)
    Axillary hyperhidrosis (Botox) — dosing/interval
    Total unitsUp to 100 units (50 units per axilla)
    Dosing intervalEvery 12 weeks
    Product specifiedonabotulinumtoxinA (Botox)

    Prior Authorization, Step Therapy, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for all botulinum toxin therapies prior to administration. Requests must document the specific indication, relevant diagnostic information, prior trials or contraindications of alternative botulinum products when applicable, and the proposed dosing interval. Authorization will be limited to indication-specific quantity and frequency limits (see Appendix 1).

    • All botulinum toxin products require prior authorization.
    • Include diagnosis, indication-specific documentation, and planned dose/frequency.
    • Approval limited to Appendix 1 quantity/frequency limits.
    Step Therapy

    Step Therapy Between Botulinum Products

    Step therapy requirements apply when onabotulinumtoxinA (Botox) is requested for many indications. Providers must document trials of preferred alternative botulinum toxin products (e.g., incobotulinumtoxinA/Xeomin and/or abobotulinumtoxinA/Dysport) that were ineffective, contraindicated, or not tolerated per indication-specific criteria.

    Clinical Background

    Botulinum toxin products are used across specialties for both therapeutic and aesthetic purposes; however, this policy distinguishes clinical indications from cosmetic uses. Therapeutic uses (covered when criteria are met) include neurologic and urologic conditions such as dystonias, spasticity, chronic sialorrhea, blepharospasm, chronic migraine prevention, and bladder dysfunction. By contrast, products or formulations approved and used primarily for improving facial appearance (for example, Botox Cosmetic, Jeuveau, Xeomin for upper facial lines, and Daxxify for glabellar lines) fall under the policy’s cosmetic exclusion and are not covered.

    Definitions and Diagnostic Thresholds

    Chronic migraine — diagnostic threshold
    Diagnostic threshold>= 15 headache days per month
    Duration requirementFor at least the previous 3 months
    Age requirement (policy context)Aged >= 18 years for prophylaxis initiation
    Policy Summary
    PayerCommunity-Care
    PolicyBotulinum toxin products — medical coverage criteria
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewAug 1, 2025
    Next Review DateAug 1, 2025
    Key ActionObtain prior authorization and document indication-specific diagnostic and trial criteria (including pediatric weight when applicable).
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling Codes and Quantity LimitsPrior Authorization, Step Therapy, and DocumentationClinical BackgroundDefinitions and Diagnostic Thresholds
    Blepharospasm (Botox) — max units/interval
    Maximum units per 30 daysUp to 200 units per 30 day period
    Minimum interval between treatments12 weeks between treatment
    Product specifiedonabotulinumtoxinA (Botox)
    Strabismus (Botox) — units per muscle
    Units per muscleUp to 25 units per muscle
    Product specifiedonabotulinumtoxinA (Botox)
    Reference noteSee package insert for per-site dose limitations
    Chronic sialorrhea (adult, Botox) — units/interval
    Adult dosingUp to 100 units
    Dosing intervalEvery 16 weeks
    Product specifiedonabotulinumtoxinA (Botox)
    Chronic sialorrhea (pediatric, Botox) — weight-based dosing/interval
    Pediatric maximumUp to 75 units (weight-based)
    Dosing intervalUp to every 16 weeks
    Documentation requirementMember weight required for pediatric quantity approvals
    • Cervical dystonia: trials of Xeomin and Dysport required (unless patient aged 16–17).
    • Blepharospasm: trial of Xeomin required (exceptions for ages 12–17).
    • Upper limb spasticity: trials of Xeomin and Dysport required.
    • Lower limb spasticity: trial of Dysport required.
    Documentation Required

    Pediatric Weight and Quantity Documentation

    For pediatric members (<18 years) where approved, weight must be provided to determine appropriate quantity dosing. Approvals and quantity limits for pediatric patients are weight-based where indicated; reference Appendix 1 and the product package insert for dose-per-site and weight-based charts.

    • A weight is required for pediatric approvals for chronic sialorrhea, neurogenic detrusor overactivity, and upper/lower limb spasticity.
    • Appendix 1 and product inserts contain pediatric unit limits and weight-based dosing charts.
    Denial Risk

    Cosmetic Use Excluded from Coverage

    Botulinum toxin products used for cosmetic purposes are excluded from coverage. This includes but is not limited to Botox Cosmetic, Jeuveau (prabotulinumtoxinA), Xeomin for upper facial lines, and Daxxify (daxibotulinumtoxinA-lanm) when used for temporary improvement of moderate to severe glabellar, forehead, or lateral canthal lines and platysmal bands.

    • Cosmetic indications (e.g., glabellar lines, lateral canthal lines, forehead lines, platysma bands) are not covered.
    • Specific excluded products include onabotulinumtoxinA (Botox Cosmetic), prabotulinumtoxinA (Jeuveau), incobotulinumtoxinA (Xeomin) for upper facial lines, and daxibotulinumtoxinA-lanm (Daxxify).